Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 312
Selected: 0
NCT IDTitle
NCT05346354Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
NCT01895127Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation
NCT04564339Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
NCT07596784Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)
NCT05389449A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH
NCT04956276Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia
NCT01193348An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome
NCT06374264Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder
NCT04920370Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects
NCT06071442Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine
NCT06079359Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP
NCT02614898Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment
NCT02235493Non-interventional Substudy of ALX-HPP-502 to Assess Natural History of Patients With Juvenile-onset HPP Who Served as Historical Controls in ENB-006-09
NCT00048308Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass
NCT06578949Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT05683678US Selumetinib Registry
NCT04248465An Efficacy and Safety Study of Ravulizumab in ALS Participants
NCT01716728Identification of Undiagnosed Lysosomal Acid Lipase Deficiency
NCT00040157Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load.
NCT02207725A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban
NCT03766347Pediatric NMOSD Observational Study
NCT06312644Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
NCT03574506Eculizumab Use in the Postpartum Period for the Treatment of Pregnancy Associated aHUS: A Case Series
NCT00380159Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A
NCT00744042Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP)
NCT00844545Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS
NCT00675844An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment
NCT02220725A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban
NCT01095887Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation
NCT04609696Study of the Metabolism of Danicopan in Healthy Adults
NCT04320602Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab
NCT03555539Study of Danicopan in Participants With Hepatic Impairment
NCT04526210Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants
NCT06015750Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia
NCT04889690Study of Multiple Doses of Danicopan in Healthy Participants
NCT02003144An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
NCT04743804Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger
NCT01371825Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency
NCT02293382A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB
NCT05565092Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease
NCT02273596Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients
NCT03580941Usefulness of a Diagnostic Algorithm to Diagnose Thrombotic Microangiopathies in Pregnancy
NCT02949128Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT05419765Lysosomal Acid Lipase Activity in Nonalcoholic Fatty Liver Disease
NCT04233073Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery
NCT00739505Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP)
NCT04551599A Study of the Effects of Food and Age on Danicopan
NCT01194804E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients
NCT04730804A Study of ALXN1830 in Healthy Adult Participants
NCT04573309Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840